We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA Holdings (IQV) Inks Technology Deal With Theramex
Read MoreHide Full Article
IQVIA Holdings Inc. (IQV - Free Report) is strengthening its technological solutions with the help of strategic collaborations.
The company recently entered into a technology partnership with Theramex, a global pharmaceutical company dedicated to women’s health.
The deal involves integration of IQVIA Holdings' Orchestrated Customer Engagement (OCE) technology solution into Theramex’s European commercial operations. Theramex will shift its existing platforms to OCE by year end.
OCE is an innovative platform designed to generate an extensive suite of customer engagement system for pharmaceutical companies to help them operate efficiently with a deeper understanding of client demands. OCE does so by deploying its advanced analytics and machine learning technologies.
A Win-win Situation
The partnership is expected to complement IQVIA Holdings’ robust growth in the Europe, Africa and Asia-Pacific regions and drive its Technology & Analytics Solutions segment.
In the first half of 2018, Technology & Analytics Solutions revenues of roughly $2 billion grew 14.2% from the year-ago period. Europe, Africa and Asia-Pacific regions contributed around 53% to the company’s total revenues and grew 10.4% year over year to $2.73 billion.
So far this year, shares of IQVIA Holdings have gained 22.8%, significantly outperforming the 14.5% rise of the industry it belongs to.
As far as Theramex is concerned, the partnership is expected to help it revamp its client engagement model and enhance client’s access to its expanding product portfolio.
Alistair Grenfell, president of IQVIA Holdings operations in the North Europe, Middle East, Africa and South Asia stated, “We are delighted Theramex has chosen to adopt this platform ahead of traditional customer relationship management solutions that offer limited flexibility and insight.”
The long-term expected EPS (three to five years) growth rate for Genpact, WEX and Broadridge is 10%, 15% and 10%, respectively.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
IQVIA Holdings (IQV) Inks Technology Deal With Theramex
IQVIA Holdings Inc. (IQV - Free Report) is strengthening its technological solutions with the help of strategic collaborations.
The company recently entered into a technology partnership with Theramex, a global pharmaceutical company dedicated to women’s health.
The deal involves integration of IQVIA Holdings' Orchestrated Customer Engagement (OCE) technology solution into Theramex’s European commercial operations. Theramex will shift its existing platforms to OCE by year end.
OCE is an innovative platform designed to generate an extensive suite of customer engagement system for pharmaceutical companies to help them operate efficiently with a deeper understanding of client demands. OCE does so by deploying its advanced analytics and machine learning technologies.
A Win-win Situation
The partnership is expected to complement IQVIA Holdings’ robust growth in the Europe, Africa and Asia-Pacific regions and drive its Technology & Analytics Solutions segment.
In the first half of 2018, Technology & Analytics Solutions revenues of roughly $2 billion grew 14.2% from the year-ago period. Europe, Africa and Asia-Pacific regions contributed around 53% to the company’s total revenues and grew 10.4% year over year to $2.73 billion.
So far this year, shares of IQVIA Holdings have gained 22.8%, significantly outperforming the 14.5% rise of the industry it belongs to.
As far as Theramex is concerned, the partnership is expected to help it revamp its client engagement model and enhance client’s access to its expanding product portfolio.
Alistair Grenfell, president of IQVIA Holdings operations in the North Europe, Middle East, Africa and South Asia stated, “We are delighted Theramex has chosen to adopt this platform ahead of traditional customer relationship management solutions that offer limited flexibility and insight.”
Zacks Rank & Stocks to Consider
Currently, IQVIA Holdings carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked stocks in the broader Business Services sector include Genpact Limited (G - Free Report) , WEX Inc. (WEX - Free Report) and Broadridge Financial Solutions, Inc. (BR - Free Report) . All the stocks carry a Zacks Rank #2 (Buy).
The long-term expected EPS (three to five years) growth rate for Genpact, WEX and Broadridge is 10%, 15% and 10%, respectively.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>